Literature DB >> 30470837

MMSET I acts as an oncoprotein and regulates GLO1 expression in t(4;14) multiple myeloma cells.

Zhigang Xie1, Jing Yuan Chooi2, Sabrina Hui Min Toh1, Dongxiao Yang3, Nurhidayah Binte Basri3, Ying Swan Ho3, Wee Joo Chng4,5,6.   

Abstract

Multiple myeloma (MM) is characterized by recurrent chromosomal translocations. T(4;14) MM overexpresses multiple myeloma SET domain-containing protein (MMSET). MMSET has three major isoforms: the full-length form MMSET II and the short isoforms REIIBP and MMSET I. Here we show that the short isoform MMSET I is an oncoprotein that promoted cell survival and tumorigenesis in vitro and in vivo. Gene expression array analysis indicated that MMSET I increased glyoxalase I (GLO1) expression. Chromatin immunoprecipitation (ChIP) coupled with qPCR indicated that MMSET I bound upstream of the GLO1 transcription start site. Ectopic overexpression of MMSET I or its mutants showed MMSET I depended on its C terminus to regulate GLO1 expression. GLO1 knockdown (KD) induced apoptosis and reduced colony formation. MMSET I or GLO1 KD reduced the levels of anti-apoptosis factors such as MCL1 and BCL2. Ectopic overexpression of GLO1 resulted in the significant rescue of KMS11 cells from MMSET I KD-induced apoptosis and glycolysis inhibition. This suggested that GLO1 may be of functional importance target downstream of MMSET I. Cumulatively, our study suggests that MMSET I is an oncoprotein and potential therapeutic target for t(4;14) MM.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30470837     DOI: 10.1038/s41375-018-0300-0

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  53 in total

1.  Identification and characterization of a novel human histone H3 lysine 36-specific methyltransferase.

Authors:  Xiao-Jian Sun; Ju Wei; Xin-Yan Wu; Ming Hu; Lan Wang; Hai-Hong Wang; Qing-Hua Zhang; Sai-Juan Chen; Qiu-Hua Huang; Zhu Chen
Journal:  J Biol Chem       Date:  2005-08-22       Impact factor: 5.157

Review 2.  Molecular pathogenesis and a consequent classification of multiple myeloma.

Authors:  P Leif Bergsagel; W Michael Kuehl
Journal:  J Clin Oncol       Date:  2005-09-10       Impact factor: 44.544

3.  A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript.

Authors:  Madhumita Santra; Fenghuang Zhan; Erming Tian; Bart Barlogie; John Shaughnessy
Journal:  Blood       Date:  2002-11-14       Impact factor: 22.113

4.  Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients.

Authors:  Jonathan J Keats; Christopher A Maxwell; Brian J Taylor; Michael J Hendzel; Marta Chesi; P Leif Bergsagel; Loree M Larratt; Michael J Mant; Tony Reiman; Andrew R Belch; Linda M Pilarski
Journal:  Blood       Date:  2005-01-27       Impact factor: 22.113

Review 5.  Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma.

Authors:  Jonathan J Keats; Tony Reiman; Andrew R Belch; Linda M Pilarski
Journal:  Leuk Lymphoma       Date:  2006-11

6.  NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming.

Authors:  Alex J Kuo; Peggie Cheung; Kaifu Chen; Barry M Zee; Mitomu Kioi; Josh Lauring; Yuanxin Xi; Ben Ho Park; Xiaobing Shi; Benjamin A Garcia; Wei Li; Or Gozani
Journal:  Mol Cell       Date:  2011-11-18       Impact factor: 17.970

Review 7.  Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma.

Authors:  P Leif Bergsagel; W Michael Kuehl
Journal:  Immunol Rev       Date:  2003-08       Impact factor: 12.988

8.  The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor.

Authors:  Jotin Marango; Manabu Shimoyama; Hitomi Nishio; Julia A Meyer; Dong-Joon Min; Andres Sirulnik; Yolanda Martinez-Martinez; Marta Chesi; P Leif Bergsagel; Ming-Ming Zhou; Samuel Waxman; Boris A Leibovitch; Martin J Walsh; Jonathan D Licht
Journal:  Blood       Date:  2007-12-21       Impact factor: 22.113

9.  The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity.

Authors:  Josh Lauring; Abde M Abukhdeir; Hiroyuki Konishi; Joseph P Garay; John P Gustin; Qiuju Wang; Robert J Arceci; William Matsui; Ben Ho Park
Journal:  Blood       Date:  2007-10-17       Impact factor: 22.113

10.  In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression.

Authors:  Jonathan J Keats; Tony Reiman; Christopher A Maxwell; Brian J Taylor; Loree M Larratt; Michael J Mant; Andrew R Belch; Linda M Pilarski
Journal:  Blood       Date:  2002-10-03       Impact factor: 22.113

View more
  7 in total

Review 1.  Molecular basis of clonal evolution in multiple myeloma.

Authors:  Yusuke Furukawa; Jiro Kikuchi
Journal:  Int J Hematol       Date:  2020-02-06       Impact factor: 2.490

2.  Inhibition of the Protein Arginine Methyltransferase PRMT5 in High-Risk Multiple Myeloma as a Novel Treatment Approach.

Authors:  Philip Vlummens; Stefaan Verhulst; Kim De Veirman; Anke Maes; Eline Menu; Jérome Moreaux; Hugues De Boussac; Nicolas Robert; Elke De Bruyne; Dirk Hose; Fritz Offner; Karin Vanderkerken; Ken Maes
Journal:  Front Cell Dev Biol       Date:  2022-06-08

3.  WHSC1 Promotes Cell Proliferation, Migration, and Invasion in Hepatocellular Carcinoma by Activating mTORC1 Signaling.

Authors:  Jingjing Dai; Longfeng Jiang; Lei Qiu; Yuyun Shao; Ping Shi; Jun Li
Journal:  Onco Targets Ther       Date:  2020-07-20       Impact factor: 4.147

4.  The NSD2 p.E1099K Mutation Is Enriched at Relapse and Confers Drug Resistance in a Cell Context-Dependent Manner in Pediatric Acute Lymphoblastic Leukemia.

Authors:  Joanna Pierro; Jason Saliba; Sonali Narang; Gunjan Sethia; Shella Saint Fleur-Lominy; Ashfiyah Chowdhury; Anita Qualls; Hannah Fay; Harrison L Kilberg; Takaya Moriyama; Tori J Fuller; David T Teachey; Kjeld Schmiegelow; Jun J Yang; Mignon L Loh; Patrick A Brown; Jinghui Zhang; Xiaotu Ma; Aristotelis Tsirigos; Nikki A Evensen; William L Carroll
Journal:  Mol Cancer Res       Date:  2020-04-24       Impact factor: 5.852

5.  NSD2 promotes tumor angiogenesis through methylating and activating STAT3 protein.

Authors:  Da Song; Jingqin Lan; Yaqi Chen; Anyi Liu; Qi Wu; Chongchong Zhao; Yongdong Feng; Jing Wang; Xuelai Luo; Zhixin Cao; Xiaonian Cao; Junbo Hu; Guihua Wang
Journal:  Oncogene       Date:  2021-03-19       Impact factor: 9.867

6.  Targeting NSD2-mediated SRC-3 liquid-liquid phase separation sensitizes bortezomib treatment in multiple myeloma.

Authors:  Jing Liu; Ying Xie; Jing Guo; Xin Li; Jingjing Wang; Hongmei Jiang; Ziyi Peng; Jingya Wang; Sheng Wang; Qian Li; Linquan Ye; Yuping Zhong; Qiguo Zhang; Xiaozhi Liu; David M Lonard; Jin Wang; Bert W O'Malley; Zhiqiang Liu
Journal:  Nat Commun       Date:  2021-02-15       Impact factor: 14.919

Review 7.  Mitochondrial metabolic determinants of multiple myeloma growth, survival, and therapy efficacy.

Authors:  Remya Nair; Pulkit Gupta; Mala Shanmugam
Journal:  Front Oncol       Date:  2022-09-16       Impact factor: 5.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.